What You Should Know:
– Personalis, Inc. announced a significant expansion and extension of its strategic collaboration with Tempus AI, Inc. that adds colorectal cancer (CRC) as a new indication to their existing, exclusive commercialization partnership.
– Personalis and Tempus will now work together to bring the NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test to market for detecting cancer recurrence across four key areas: breast, lung, and colorectal cancers, and solid tumor immunotherapy monitoring.
Accelerating Adoption of NeXT Personal MRD Testing
Personalis has amended its agreement with Tempus to further accelerate the adoption of NeXT Personal. The updated terms of the collaboration include:
- Expanded Indications: Colorectal cancer is added as the fourth indication for which Tempus will serve as Personalis’ exclusive commercial partner.
- Extended Term: The initial agreement term is extended to November 2029.
- Lengthened Exclusivity: Tempus’ exclusivity for all four indications (breast, lung, colorectal cancers, and solid tumor immunotherapy monitoring) is extended through 2028.
The addition of CRC follows the presentation of compelling interim analysis results from the VICTORI study at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which demonstrated the strong performance of NeXT Personal for detecting early signs of residual or recurrent CRC. Colorectal cancer affects over 150,000 new patients in the U.S. annually, with many experiencing recurrence after initial treatment.
“This deepened collaboration is a key component of our ‘Win in MRD’ strategy,” said Chris Hall, CEO of Personalis. “Every day, thousands of cancer survivors live with the uncertainty of whether their cancer will return. By expanding our collaboration with Tempus to include CRC, we’re bringing peace of mind to more patients while building the evidence needed for broad reimbursement coverage for multiple indications.”
